Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Effect of Cryopreservation in Unrelated Bone Marrow and Peripheral Blood Stem Cell Transplantation in the Era of the COVID-19 Pandemic: An Update from the Japan Marrow Donor Program

Yoshinobu Kanda1,19,*, Noriko Doki2, Minoru Kojima3, Shinichi Kako4, Masami Inoue5,19, Naoyuki Uchida6,19, Yasushi Onishi7,19, Reiko Kamata8,19, Mika Kotaki9,19, Ryoji Kobayashi9,19, Junji Tanaka10,19, Takahiro Fukuda11,19, Nobuharu Fujii11,19, Koichi Miyamura12,19, Shin-Ichiro Mori13,19, Yasuo Mori14,19, Yasuo Morishima15,19, Hiromasa Yabe16,19, Yoshiko Atsuta17,19, Yoshihisa Kodera18

1 Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan
2 Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Konagome Hospital, Tokyo, Japan
3 Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
4 Department of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan
5 Department of Hematology/Oncology, Osaka Women’s and Children’s Hospital, Osaka, Japan
6 Department of Hematology, Toranomon Hospital, Tokyo, Japan
7 Department of Hematology, Tohoku University Hospital, Sendai, Japan
8 Nonprofit Organization Blood Disorder Information and Support Service “Tsubasa”, Tokyo, Japan
9 Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokkai Hospital, Sapporo, Japan
10 Department of Hematology, Tokyo Women’s Medical University, Tokyo, Japan
11 Division of Blood Transfusion, Okayama University Hospital, Okayama, Japan
12 Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
13 Hematology Department, St. Luke’s International Hospital, Tokyo, Japan
14 Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
15 Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan
16 Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Japan
17 Japanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan
18 Medical Committee of the Japan Marrow Donor Program, Tokyo, Japan

ABSTRACT

During the COVID-19 pandemic, donor grafts are frequently cryopreserved to ensure that a graft is available before starting a conditioning regimen. However, there have been conflicting reports on the effect of cryopreservation on transplantation outcomes. Also, the impact of cryopreservation may differ in bone marrow (BM) transplantation (BMT) and peripheral blood stem cell (PBSC) transplantation (PBSCT). In this retrospective study, we analyzed the clinical data of both cryopreserved unrelated BMTs (n = 235) and PBSCTs (n = 118) and compared these with data from a large control cohort without cryopreservation including 4133 BMTs and 720 PBSCTs. Among the patients with cryopreserved grafts, 10 BMT recipients (4.3%) and 3 PBSCT recipients (2.5%) did not achieve neutrophil engraftment after transplantation, including 4 of the former and all 3 of the latter who died early before engraftment. In a multivariate analysis, cryopreservation was not associated with neutrophil engraftment in BMT but significantly delayed neutrophil engraftment in PBSCT (hazard ratio [HR], .82; 95% confidence interval [CI], .69 to .97; P = .023). There was an interaction with borderline significance between cryopreservation and the stem cell source (P = .067). Platelet engraftment was delayed by cryopreservation after both BMT and PBSCT. Only 2 cryopreserved grafts (<1%) were unused during the study period. The cryopreservation of unrelated donor BM and PBSCT grafts is associated with a slight delay in neutrophil and platelet engraftment but an acceptable rate of graft failure. PBSCT grafts

*Correspondence and reprint requests: Yoshinobu Kanda, Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-cho, Tochigi, 329-0498, Japan
E-mail address: ycanda-tky@umin.ac.jp (Y. Kanda).
INTRODUCTION
During the COVID-19 pandemic, the Japan Marrow Donor Program (JMDP) is allowing the cryopreservation of donor grafts as an exception to ensure that grafts are available before starting a conditioning regimen. Similarly, the National Marrow Donor Program (NMDP) is temporarily requiring that transplantation centers plan cryopreservation of unrelated and related donor products facilitated by the NMDP. Although previous studies have shown that the cryopreservation of allogeneic donor grafts is both safe and effective, others have raised concerns regarding the deleterious effects of the cryopreservation of donor cells.

We previously reported that the cryopreservation of unrelated bone marrow (BM) grafts did not affect neutrophil engraftment irrespective of the time from stem cell harvest to cryopreservation. However, the safety of cryopreservation of unrelated peripheral blood stem cell (PBSC) grafts was not analyzed in detail, owing to the small number of patients. Since then, we have accumulated 3 times more clinical data on the cryopreservation of both unrelated BM and PBSC grafts and reanalyzed the results of neutrophil and platelet engraftment, including a comparison with the data in a large control cohort without cryopreservation.

METHODS
Patients
The policy for the cryopreservation of unrelated donor graft has been described previously. In brief, the JMDP Central Office reviewed all requests for cryopreservation of stem cells. After approval, stem cells were harvested and shipped from harvest centers to transplantation centers and then cryopreserved at the transplantation centers. Clinical data on unrelated cryopreserved BM and PBSC grafts were collected from the transplantations performed between January 2016 and December 2018. Questionnaires were sent to transplantation centers regarding the total 360 unrelated transplantations, and clinical data for 235 recipients of cryopreserved BM grafts and 118 recipients of cryopreserved PBSC grafts were collected. The median age of the BM recipients was 50.0 years (interquartile range IQR, 36.0 to 61.0 years), and that of PBSC recipients was 53.0 years (IQR, 42.25 to 61.75 years) (Table 1). There was an HLA mismatch in approximately 40% of the transplantations.

RESULTS
Patients and Stem Cell Grafts
During the study period, 242 of 1342 (18.0%) unrelated BM and 118 of 435 (27.1%) of unrelated PBSC were facilitated by the JMDP. The primary endpoint was neutrophil engraftment, defined as the first of 3 consecutive days with an absolute neutrophil count of at least 5 x 10^9/L, and the secondary endpoint was platelet engraftment. Approximately 40% of the transplantations were performed using cryopreserved grafts. Two other BM grafts were cryopreserved but not infused owing to patient death and a freezer problem. Questionnaires were sent to transplantation centers regarding the total 360 unrelated transplantations, and clinical data for 235 recipients of cryopreserved BM grafts and 118 recipients of cryopreserved PBSC grafts were collected. The median age of the BM recipients was 50.0 years (interquartile range IQR, 36.0 to 61.0 years), and that of PBSC recipients was 53.0 years (IQR, 42.25 to 61.75 years) (Table 1). There was an HLA mismatch in approximately 40% of the transplantations.

In the noncryopreservation cohort, 4133 patients received BM grafts and 720 received PBSC grafts, excluding 7 patients without engraftment data. The median age of...
the patients who underwent BMT was 50.0 years (IQR, 34.0 to 60.0 years) and that of PBSCT recipients was 53.0 years (IQR, 42.0 to 61.0 years).

**Outcomes of Cryopreserved Graft Recipients**

Ten (4.3%) BMT recipients and 3 (2.5%) PBSCT recipients did not achieve neutrophil engraftment. Of these, 4 of the former and 3 of the latter died early before engraftment. The cause of death was infection in 4 patients and progression of underlying malignancy, diffuse alveolar hemorrhage, and multiorgan failure after early rescue transplantation on day 16 in 1 patient each. The other 6 patients who did not achieve neutrophil engraftment were considered to have graft failure, and none were in remission before transplantation. In 4 of these patients, graft failure was attributed to persistent hematologic malignancy. One patient showed hematologic recovery, but chimerism analysis revealed autologous hematopoiesis. The cause of graft failure in the remaining patient was considered to be hemophagocytic lymphohistiocytosis.

The median time to neutrophil engraftment was 18 days (95% confidence interval [CI], 17 to 19 days) after cryopreserved BMT and 16 days (95% CI, 15 to 17 days) after cryopreserved PBSCT. The incidence of neutrophil engraftment at day +28 was 93.6% and 94.9%, respectively. The median days to platelet engraftment was 34 days (95% CI, 32 to 35 days) after cryopreserved BMT and 26 days (95% CI, 23 to 28 days) after cryopreserved PBSCT. The incidence of platelet engraftment at day +28 was 32.3% and 61.9%, respectively.

Data on the time between graft harvest and graft freezing were available in patients who received cryopreserved grafts. We grouped patients into the longest one-third, shortest one-third, and remaining patients. After cryopreserved BMT, neutrophil engraftment was slightly delayed in the shortest group (median of 19, 18, and 18 days, respectively, in the 3 groups), but the median time to platelet engraftment was equivalent among the 3 groups (32, 33, and 32 days). After cryopreserved PBSCT, the times to neutrophil and platelet engraftment were not different among the 3 groups (median of 15, 15, and 16 days for neutrophil engraftment and 30, 30, and 28 days for platelet engraftment).

**Comparison of Cryopreserved and Noncryopreserved Grafts**

Characteristics of the patients who received cryopreserved and noncryopreserved grafts are summarized in Table 2. There were significant between-group differences in background diseases and disease status. The numbers of harvested nuclear cells and CD34+ cells did not differ between BM and PBSC grafts. Univariate analysis showed no difference in neutrophil engraftment between recipients of cryopreserved grafts and recipients of noncryopreserved grafts in both BMT and PBSCT, although there was a slight tendency toward delayed engraftment in the cryopreservation group in PBSCT recipients (Figure 1A,B). After adjustment for age, myeloid disease, disease status, and HLA mismatch by a multivariate analysis, cryopreservation was not associated with neutrophil engraftment in BMT (hazard ratio [HR], .98; 95% CI .87 to 1.10; \( P = .74 \)). However, cryopreservation significantly delayed neutrophil engraftment in PBSCT (HR, .82; 95% CI .69 to .97; \( P = .023 \)) (Table 3). There was an interaction with borderline significance between cryopreservation and the stem cell source (HR, .78; 95% CI .60 to 1.02; \( P = .067 \)).

Platelet engraftment was delayed by cryopreservation for both BMT and PBSCT (Figure 2A,B). This result was confirmed by multivariate analyses adjusted for age, myeloid disease, disease status, and HLA mismatch (HR, .75; 95% CI .66 to .87; \( P < .0001 \) after BMT and HR, .74; 95% CI .61 to .90; \( P = .0029 \)).

---

**Table 2**

Patient Characteristics Grouped According to the Use of Cryopreservation in BMT and PBSCT

| Characteristic                      | Cryopreservation | PValue | SMD   |
|-------------------------------------|------------------|--------|-------|
| **BMT**                             |                  |        |       |
| No. of patients                     | 4140             | 235    |       |
| Age, yr, median (IQR)               | 50.0(34.0-60.0)  | 50.0(36.0-61.0) | .545 | .047  |
| Disease, n (%)                      |                  |        |       |
| Leukemia                            | 2289             | 119    | .009  | .226  |
| Lymphoma/myeloma                    | 658              | 27     |       |
| MDS/MPN                             | 630              | 68     |       |
| No malignancy                       | 363              | 21     |       |
| Disease status, n (%)               |                  |        |       |
| CR                                 | 1647             | 120    | .001  | .228  |
| NR                                 | 2493             | 115    |       |
| Myeloid malignancies, n (%)         |                  |        |       |
| Others                              | 1833             | 86     | .015  | .167  |
| Myeloid                             | 2287             | 140    |       |
| HLA mismatch, n (%)                 |                  |        |       |
| No                                  | 2233             | 131    | .638  | .034  |
| Yes                                 | 1900             | 104    |       |
| Harvested nuclear cells, \( \times 10^{10} \), median (IQR) | 13.9(10.3-17.7) | 13.9(10.0-17.7) | .66  | .017  |
| **PBSCT**                           |                  |        |       |
| No. of patients                     | 720              | 118    |       |
| Age, yr, median (IQR)               | 53.0(42.0-61.0)  | 53.0(42.3-61.8) | .867 | .002  |
| Disease, n (%)                      |                  |        |       |
| Leukemia                            | 426              | 74     | .326  | .164  |
| Lymphoma/myeloma                    | 113              | 13     |       |
| MDS/MPN                             | 176              | 29     |       |
| No malignancy                       | 5(7)             | 2(17)  |       |
| Disease status, n (%)               |                  |        |       |
| CR                                 | 274              | 71     | -.001 | .454  |
| NR                                 | 446              | 47     |       |
| Myeloid malignancies, n (%)         |                  |        |       |
| Others                              | 235              | 35     | .595  | .064  |
| Myeloid                             | 485              | 83     |       |
| HLA mismatch, n (%)                 |                  |        |       |
| No                                  | 430              | 72     | .84   | .023  |
| Yes                                 | 288              | 46     |       |
| Harvested CD34+ cells, \( \times 10^{5} \), median (IQR) | 2.4(1.5-3.7) | 2.7(1.8-4.2) | .11  | .17   |

SMD indicates standardized mean difference.
after PBSCT) (Table 3). There was no significant interaction between cryopreservation and the stem cell source (HR, .98; 95% CI, .74 to 1.30; \( P = .90 \)).

**DISCUSSION**

The cryopreservation of BM and PBSC grafts ensures that they are available before the start of conditioning and has been used frequently during the COVID-19 pandemic. There has been some concern about stem cell damage from the procedure, but several studies have shown no significant delay in hematopoietic recovery after transplantation of cryopreserved stem cells [2–6]. On the other hand, a retrospective study showed delayed neutrophil and platelet engraftment with the use of cryopreserved PBSC grafts with no effect on overall survival [9]. Eapen et al. [7] reported that the use of cryopreserved grafts was associated with increased graft failure and 1-year mortality after transplantation for aplastic anemia, in which two-thirds of the cases involved BM grafts and one-third involved PBSC grafts. In addition, in a recent large-scale retrospective study by the Center for International Blood and Marrow Transplant Research (CIBMTR), the use of cryopreserved graft significantly delayed neutrophil and platelet engraftment in PBSCT but not in BMT [8]. In unrelated PBSC, overall survival was significantly inferior with cryopreserved grafts; however, more than one-half of the cases involving cryopreservation were due to the patient condition including changes in disease status, reaction to conditioning regimen, and infection. Multivariate analysis revealed significantly shorter survival in patients who received cryopreserved grafts because of their condition; thus, the reasons for cryopreservation are important when comparing cryopreserved and noncryopreserved grafts.

In the era of the COVID-19 pandemic, donor grafts are cryopreserved mainly to ensure their availability before the start of the conditioning regimen. Devine et al. [12] recently compared the outcomes of patients who underwent cryopreserved BMT or PBSCT between March and August 2020 with those of recipients of noncryopreserved BMT or PBSCT in 2019 using the CIBMTR database. Neutrophil and platelet engraftment were delayed after cryopreservation, but there were no significant differences in the incidence of graft failure and overall mortality.

In the current study, cryopreservation was performed exclusively to ensure graft availability. Similar to the recent CIBMTR study, the time to engraftment was longer after cryopreservation, but the effect on neutrophil engraftment was more prominent in PBSCT than in BMT, although the incidence of graft failure was not increased. In previous studies analyzing

---

**Table 3**

Multivariate Analyses for Neutrophil and Platelet Engraftment after Unrelated BMT and PBSCT

| Factor                  | Neutrophil Engraftment | Platelet Engraftment |
|-------------------------|------------------------|----------------------|
|                         | HR (95% CI)            | \( P \) Value        | HR (95% CI)            | \( P \) Value |
| **BMT**                 |                        |                      |                        |              |
| Age                     | 1.00 (.99–1.00)        | .27                  | 1.00 (.99–1.00)        | <.0001       |
| Not in remission        | .83 (.78–.88)          | <.0001               | .76 (.72–.82)          | <.0001       |
| Myeloid malignancies    | .92 (.87–.98)          | .0092                | .98 (.91–1.04)         | .48          |
| HLA mismatch            | .88 (.84–.93)          | <.0001               | .80 (.75–.86)          | <.0001       |
| Cryopreservation        | .98 (.87–1.1)          | .74                  | .75 (.66–.87)          | <.0001       |
| **PBSCT**               |                        |                      |                        |              |
| Age                     | 1.00 (.99–1.00)        | .3                   | 1.00 (.99–1.00)        | .11          |
| Not in remission        | .90 (.79–1.02)         | .11                  | .72 (.62–.83)          | <.0001       |
| Myeloid malignancies    | 1.01 (.87–1.16)        | .92                  | 1.07 (.92–1.24)        | .4           |
| HLA mismatch            | 1.02 (.9–1.16)         | .75                  | .94 (.81–1.08)         | .38          |
| Cryopreservation        | .82 (.69–.97)          | .023                 | .74 (.61–.9)           | .0029        |
the impact of cryopreservation separately in BMT and PBSCT, a similar tendency toward a stronger effect in PBSCT has been observed (Table 4) [8,13]. Therefore, PBSC grafts may be more sensitive to cryopreservation than BM grafts.

Another concern has been that the cryopreservation of donor grafts may increase the number of unused grafts. The NMDP reported that 222 of 9294 products (2.4%) collected from March 17, 2020, through June 30, 2021, were not infused for a variety of reasons, including patient death, patient choice, poor product quality, clumps in the product, viability, a positive culture, and others [14]. However, the proportion of noninfused grafts decreased over time, likely because transplantation centers and apheresis centers became more adept at cryopreservation during the study period. In fact, in the earlier report during the COVID-19 pandemic, transplantation centers reported problems with 29% of the products, including damage during transit, low cell dose, inadequate labeling, missing representative samples, and missing documentation, which resulted in noninfused products in 22 of 191 (12%) collections [15]. On the other hand, only 2 cryopreserved grafts (<1%) were not infused in Japan during the study period. The policy of the JMDP to strictly restrict cryopreservation of donor grafts before the COVID-19 pandemic might have contributed to the high awareness in transplantation centers of the importance of limiting the number of unused grafts.

A major limitation of this study is the lack of clinical outcomes other than engraftment, such as the incidences of GVHD and nonrelapse mortality. In previous studies, the effect

---

**Table 4**

Summary of Studies Comparing Cryopreserved and Noncryopreserved Grafts with Regard to Clinical Outcomes [4-9,12,13,17-24]

| Authors          | Year  | Source       | Cryopreserved | Noncryopreserved | Neutrophil Engraftment | Platelet Engraftment | Acute GVHD | Chronic GVHD |
|------------------|-------|--------------|---------------|------------------|------------------------|----------------------|------------|--------------|
| Eckardt et al.   | 1993  | BM           | 10            | 33               | No difference          | No difference        | Decreased  | ND           |
| Stockschläder et al. | 1997  | BM           | 40            | 40               | No difference          | No difference        | No difference | No difference|
| Kim et al.       | 2007  | PB           | 105           | 106              | No difference          | ND                   | ND         | ND           |
| Lioznov et al.   | 2008  | PB           | 31            | 493              | Increased graft failure| No difference        | ND         | ND           |
| Lioznov et al.   | 2008  | BM           | 8             | 14               | No difference          | ND                   | ND         | ND           |
| Medd et al.      | 2013  | PB           | 76            | 123              | Delayed                | No difference        | Increased  | ND           |
| Parody et al.    | 2013  | PB           | 224           | 107              | Faster                 | No difference        | Increased  | No difference|
| Dagdas et al.    | 2020  | PB           | 30            | 42               | Delayed                | No difference        | No difference | No difference|
| Eapen et al.     | 2020  | BM or PB     | 52            | 194              | Increased 1-yr         | No difference        | No difference | No difference|
| Alotaibi et al.  | 2021  | PB           | 310           | 648              | No difference          | No difference        | Increased  | ND           |
| Hamadani et al.  | 2020  | BM or PB     | 274           | 1080             | No difference          | No difference        | Decreased  | ND           |
| Fernandez-Sojo et al. | 2021 | PB           | 32            | 32               | No difference          | No difference        | No difference | No difference|
| Valentin et al.  | 2021  | PB           | 32            | 106              | No difference          | No difference        | ND         | ND           |
| Maurer et al.    | 2021  | Related PB   | 101           | 203              | Delayed                | No difference        | ND         | Increased  |
| Hsu et al.       | 2021  | Related PB   | 1051          | 3030             | No difference          | Delayed              | Increased  | ND           |
| Hsu et al.       | 2021  | Unrelated PB | 678           | 2028             | Delayed                | No difference        | No difference | No difference|
| Hsu et al.       | 2021  | BM           | 154           | 456              | Delayed                | No difference        | No difference | No difference|
| Novitzky-Basso et al. | 2022 | PB           | 135           | 348              | Delayed                | No difference        | No difference | Decreased  |
| Devine et al.    | 2021ASH | BM or PB     | 959           | 2499             | Delayed                | Delayed              | ND         | ND           |
| Current study    | 2022  | PB           | 118           | 720              | Delayed                | No difference        | ND         | ND           |
| Current study    | 2022  | BM           | 235           | 4133             | No difference          | Delayed              | ND         | ND           |

ND indicates not described.

* Transplantation only for aplastic anemia. All used post-transplantation cyclophosphamide.
of cryopreservation on the incidences of acute and chronic GVHD has been inconsistent, but several recent studies of cryopreserved PBST have reported an increased incidence of acute GVHD compared with noncryopreserved PBST (Table 4). In addition, data on the viability of graft cells before and after cryopreservation were not available in this study. In this study, we observed a stronger effect of cryopreservation on PBSC grafts compared with BM grafts. A possible explanation for this difference might be the difference in time between graft collection and cryopreservation. When apheresis for 2 days was required to collect a sufficient number of CD34+ cells, cells collected on the first day may be transferred together with those collected on the second day, leading to a longer time between collection and freezing for the graft collected on the first day. However, the time from collection to freezing was not associated with time to engraftment in the current cohort. The different effects of cryopreservation between BMT and PBST were observed only for neutrophil engraftment and not for platelet engraftment; therefore, the difference might be due to the sensitivity of the mobilized myeloid progenitor cells. Viability data for graft cells in each lineage before and after cryopreservation are needed to further clarify the difference in sensitivity between BM and PBSC grafts. Another limitation of this study is the lack of information on infectious events before neutrophil engraftment, which might have affected the time to neutrophil engraftment. However, previous studies including ours have shown an association between high-risk malignant disease and a higher incidence of bloodstream infection before engraftment [16], and in the current study, cryopreserved graft recipients were significantly more frequently in remission before transplantation. Thus, it is unlikely that an infectious event before engraftment was the major reason for the delayed engraftment after transplantation of cryopreserved grafts.

In conclusion, the cryopreservation of unrelated donor BM and PBSC grafts is associated with slight delays in neutrophil and platelet engraftment but with an acceptable rate of graft failure. Cryopreservation is a reasonable option in the era of the COVID-19 pandemic, provided that the apheresis and transplantation centers are adept at cryopreservation. Further analyses are warranted when the data on clinical outcomes, including the incidence of GVHD and nonrelapse mortality, become available.

Conflict of interest statement: There are no conflicts of interest to report.

REFERENCES

1. National Marrow Donor Program. NMDP/Be The Match response to COVID-19. Available at: https://network.bethematch.org/news/nmdp/be-the-match-response-to-covid-19/. Accessed on April, 15.
2. Stocksclader M, Kruger W, tom Dieck A, et al. Use of cryopreserved bone marrow in unrelated allogeneic transplantation. Bone Marrow Transplant. 1996;17:197–199.
3. Stocksclader M, Kruger W, Kroshchke G, et al. Use of cryopreserved bone marrow in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:569–572.
4. Stocksclader M, Hassian HT, Kroq C, et al. Long-term follow-up of leukaemia patients after related cryopreserved allogeneic bone marrow transplantation. Br J Haematol. 1997;96:382–386.
5. Kim DH, Jamal N, Saragosa R, et al. Similar outcomes of cryopreserved allo-genic peripheral stem cell transplants (PBST) compared to fresh allo-grafts. Biol Blood Marrow Transplant. 2007;13:1233–1243.
6. Hamadani M, Zhang MJ, Tang XY, et al. Cryopreservation does not impact overall survival after allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2020;26:1312–1317.
7. Eapen M, Zhang MJ, Tang XY, et al. Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anaemia. Bone Marrow Transplant. 2020;26:e161–e166.
8. Hsu JW, Farhadfar N, Murthy H, et al. The effect of donor graft cryopreserva-tion on allogeneic hematopoietic cell transplantation outcomes: a Center for International Blood and Marrow Transplant Research analysis. Implications during the COVID-19 pandemic. Transplant Cell Ther. 2021;27:507–516.
9. Mead P, Nagra S, Hollyman D, Craddock C, Malladi R. Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival. Bone Marrow Transplant. 2013;48:243–248.
10. Kanda Y, Inoue M, Uchida N, et al. Cryopreservation of unrelated hematopoietic stem cells from a blood and marrow donor bank during the COVID-19 pandemic: a nationwide survey by the Japan Marrow Donor Program. Transplant Cell Ther. 2021;27:664.e1–664.e6.
11. Kanda Y. Investigation of the freely available easy-to-use software EZR for statistical calculations. Bone Marrow Transplant. 2013;48:452–458.
12. Devine S, Kuxhausen M, Spellman SR, et al. Cryopreservation of allogeneic hematopoietic cell grafts did not adversely affect early post-transplant survival during the first six months of the COVID-19 pandemic. Blood. 2021;138(suppl 1):e2486.e1–e2496.e1 (abstract).
13. Liouzov M, Delbrugger C, Spautak A, Fehse B, Kröger N, Zander AR. Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSC, but not BM. Bone Marrow Transplant. 2008;42:121–128.
14. Stefanski HE, Newman J, Novakovich J, et al. Neither COVID-19, nor cryopreser-vation, prevented allogeneic product infusion: a report from the National Marrow Donor Program. Blood. 2021;138(suppl 1):e478.e1–e478.e1 (abstract).
15. Purtil D, Hutchins C, Kennedy G, et al. Good engraftment but quality and donor concerns for cryopreserved hematopoietic progenitor cell products collected during the COVID-19 pandemic. Transplant Cell Ther. 2021;27:1022.e1–1022.e6.
16. Kikuchi M, Akahoshi Y, Nakano H, et al. Risk factors for pre- and post-engraftment bloodstream infections after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2015;17:56–65.
17. Eckardt JR, Rodman GD, Boldt DH, et al. Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT. Bone Marrow Transplant. 1993;11:125–131.
18. Parody R, Caballero D, Márquez-Malaver FJ, et al. To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors. Eur J Haematol. 2013;91:448–455.
19. Dagdas S, Ucar MA, Ceran F, Gunes AK, Falay M, Ozet G. Comparison of allogeneic stem cell transplantations performed with frozen or fresh stem cell products with regard to GVHD and mortality. Transfus Apher Sci. 2020;59:102742.
20. Alobaidi AS, Prem S, Chen S, et al. Fresh vs. frozen allogeneic peripheral blood stem cell grafts: a successful timely option. Am J Hematol. 2021;96:179–187.
21. Fernandez-Sojo J, Azqueta C, Valdivia E, et al. Cryopreservation of unre-lated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic? Bone Marrow Transplant. 2021;56:2489–2496.
22. Valentini CG, Chiusolo P, Bianchi M, et al. Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal. Cytotherapy. 2021;23:635–640.
23. Maurer K, Kim HT, Kuczmarski TM, et al. Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconsti-tution. Blood Adv. 2021;5:5140–5149.
24. Novitzky-Basso I, Remirberger M, Chen C, et al. Anti-thymocyte globu-lins and post-transplant cyclophosphamide predisposes to inferior out-come when using cryopreserved stem cell grafts. Eur J Haematol. 2022;108:61–72.